Sunshine Biopharma, Inc.
SBFM
$1.48
$0.085.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.09% | -50.09% | 45.33% | -80.18% | -142.32% |
| Total Depreciation and Amortization | 32.69% | 11.88% | -0.92% | 1.24% | 26.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.76% | -- | -- | -- | -- |
| Change in Net Operating Assets | 22.31% | -6.34% | 54.44% | -488.41% | 94.60% |
| Cash from Operations | 42.85% | 25.70% | 49.70% | -151.16% | 70.37% |
| Capital Expenditure | 95.00% | -2,033.33% | 92.69% | 80.15% | 46.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 63.68% | -96.91% | 60.71% | -179.23% | -135.53% |
| Cash from Investing | 75.95% | -179.43% | 66.89% | 20.74% | -23.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 229.28% | -239.53% | -119.57% | 51.03% | 303.50% |
| Issuance of Common Stock | -100.00% | 932.54% | -78.04% | -14.63% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.91% | 967.79% | -83.54% | 5.13% | 6,931.47% |
| Foreign Exchange rate Adjustments | -168.01% | 3,391.18% | 98.39% | -182.26% | 199.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -145.81% | 239.62% | 38.02% | -460.58% | 111.79% |